Dialysis world news


The Remi Group Donates $20k to Local Children's Hospital - openPR (press release)
openPR (press release)
(openPR) - At the end of 2011, The Remi Group started a fundraising event called Benevolent Beards to benefit Levine Children's Hospital's Nephrology Special Needs Fund (pediatric kidney disorders). Children with kidney disorders are often required to

...

 
Dr. Jayanthi appointed urology chief at Nationwide Children's Hospital - ModernMedicine

Venkata R. Jayanthi, MD, has been appointed chief of the section of pediatric urology at Nationwide Children’s Hospital, Columbus, OH.

Dr. Jayanthi has served as a urologist at Nationwide Children’s since 1994 while also holding a faculty position in the department of urology at the Ohio State University College of Medicine, Columbus. In January 2012, he was named interim chief of pediatric urology.

"[Dr. Jayanthi’s] contributions in urologic laparoscopy and international outreach and education have garnered him great respect and acclaim nationally and internationally. His clinical excellence and commitment to compassionate care has afforded him tremendous respect locally," said R. Lawrence Moss, MD, surgeon-in-chief at Nationwide Children’s Hospital.

Dr. Jayanthi’s clinical interests include all aspects of the medical and surgical management of genitourinary problems, including conditions such as urinary tract infections, hydronephrosis, urinary incontinence, hypospadias, and intersex conditions. He is also interested in genitourinary reconstructive surgery for both congenital and acquired conditions.

Dr. Jayanthi is program director of the pediatric urology fellowship program, director of the pediatric urologic laparoscopy program, and a member of the Nephrology and Urology Research Affinity Group at Nationwide Children’s Hospital.

Go back to this issue of Urology Times eNews.

Related Content

AUA Foundation receives $1.2 million grant to renew 'rising stars' award

Academic urologist pay varies by area, department rank

...

 
Funding needed to provide the best care - The Gazette: Eastern Iowa Breaking News and Headlines (blog)

The caregiving team at DaVita Cedar Rapids was honored to welcome Fred Schuster, a staffer from Sen. Chuck Grassley’s office, to our facility recently. We welcomed the opportunity to speak with him about quality dialysis care and the importance of preventing any further cuts to the Medicare End Stage Renal Disease (ESRD) benefit that enables us to provide lifesaving care to our patients.

As a dialysis nurse for more than 12 years, I have cared for hundreds of patients who rely on quality dialysis care due to kidney failure. I am all too familiar with the issues my patients face every day, both medically and financially.

My main concern is to provide the best care to my patients, but I simply cannot succeed without the resources needed to do so. I hope Sen. Grassley will carefully consider these patients and all of the available options before enacting further cuts to the Medicare ESRD benefit. Our patients deserve nothing less.

We thank Mr. Schuster for taking the time to visit our facility to understand kidney dialysis and hear from the patients who face challenges every day.

Tracy Seboldt

Facility Administrator

DaVita Cedar Rapids

 

...

 
5 years after her kidneys shut down, Doreen Lamar knows her fate may rest with ... - Evansville Courier Press

It's late afternoon, a gorgeous spring Thursday, and Doreen Lamar is exhausted and hoarse. Thursday is one of her three days a week to spend in dialysis. Seven hours at a stretch. Week after week, month after month.

The voice will come back, but she'll be squeaky again after another session Saturday because of fluid depletion. It's one side effect the 56-year-old Perry County, Ind., native suffers after a machine filters waste from her blood, doing the job her kidneys can't.

"My blood pressure drops way down, to the 70s over the 50s — I'm really weak when I get home," she said. "Right now, dialysis is my only way to live, but it's not a nice way to live."

5 years after her kidneys shut down, Doreen Lamar knows her fate may rest with ... - Evansville Courier Press

Photo by Erin McCracken

Doreen Lamar reads a book on her Kindle as she goes through 4½ hours of dialysis at Devita Dialysis in Tell City, Ind., on Tuesday. Lamar's kidneys have been failing since 2008 following serious complications from a surgery that left her hospitalized for 13 months with the majority of that time spent on a ventilator. Lamar is on two waiting lists for a kidney and has been told the wait could be three to fouryears unless she finds a living donor. photos by ERIN McCRACKEN / COURIER & PRESS

5 years after her kidneys shut down, Doreen Lamar knows her fate may rest with ... - Evansville Courier Press

Photo by Erin McCracken

Doreen Lamar watches television as her blood runs through a dialysis machine at Devita Dialysis in Tell City, Ind. Because there are respiratory caution flags dating back to her 13 months on a ventilator, a living donor's kidney would work better because organs from a living donor usually start working right away.

She feels herself going downhill, she says: "I know I'm not as spry as I was a year ago at this time." And she knows the risks of prolonged dialysis.

Doreen Lamar needs a new kidney. She's doubtful, but hopeful, that she'll get one in time.

Doubtful if it means she must wait for a kidney from a deceased donor. Hopeful for a living donor.

That, she said, is why — for her own survival as well as that of others in similar circumstances — she is trying to get the word out to potential living donors to consider giving a kidney.

Living, giving

Living organ donorship doesn't get as much press as donorship by the deceased. Part of that may be its limited application — most organs you can't do without, so living donorship of them is out. You can live with just one kidney, so it's possible to donate one; you can donate a portion of your liver, which has the ability to regenerate in both donor and recipient; you can donate bone marrow. With some rare exceptions, that's the limit.

Kidney transplants are the most common living-donor transplants because demand is huge. On April 1, 91,656 people in the U.S. were awaiting kidney donations, according to the Organ Procurement and Transplantation Network —

more by far than awaited any other organ.

IU Health Transplants, which performed Indiana's first kidney transplant in 1965, now has completed more than 5,900. Of those, 1,800 transplants — 31 percent of the total — have been from living donors.

Several surgeries

Acute shutdown of her kidneys was just one life-threatening complication Lamar suffered almost five years ago when a surgery went awry. The Tell City resident has since been in what is termed end-stage renal failure.

Thankful to have a dialysis clinic in her town, she drives herself each Tuesday, Thursday and Saturday to the sessions that keep her alive. Then she drives back home after waiting for her blood pressure to rebound. "It's not a pretty sight to see me get in and out of a car because I'm stiff and I stagger around," she said.

Lamar's mobility problems go back more than 22 years and led eventually to a 14-hour operation in 2007 at Barnes Hospital in St. Louis in which "everything that could have gone wrong, did" — including permanent loss of kidney function.

Overweight since childhood, in her early 30s Lamar decided to change that. She revamped her eating habits and dropped 103 pounds. But after the weight loss, she found herself getting shorter in height and was having difficulty breathing.

It was 1990 when she learned she suffered from a severe case of scoliosis (curvature of the spine). Lamar knew, growing up, she had a back problem. "But my family doctor said it was because I was 'too damn fat,'" she said. "I had a more than 90-degree curve. The first three surgeries got it to 45 (degrees), which is still pretty bad."

Lamar said the best thing to come out of it all was her enduring friendship and patient relationship with Dr. John Grimm of Tri-State Orthopedic Surgeons in Evansville, who would prove a key supporter of Lamar beyond his specialist's role and remains so today. "He was floored that no (doctor) had seen (the scoliosis) before," she said.

Lamar is a self-taught computer programmer. She worked with computers 25 years before her back problems finally ended her career seven years ago. After graduation from Tell City High School in 1974, Lamar studied accounting at the University of Evansville, decided she didn't like it and left school after two years. After six months at City Chair Co. and three years as a city police dispatcher, she landed a job in 1980 at St. Meinrad Archabbey, "mounting tapes and just running jobs" as a computer operator at Abbey Press.

There, during slack periods on her 4-to-midnight shift, she studied COBOL books and learned computer programming. She became a programmer at Abbey and, in 1995, left to join a new company near Santa Claus that would eventually be called Communication Logistics. She was recruited by one of its founders, Richard Wilson, her former boss at St. Meinrad.

Fallout from a series of back surgeries after the diagnosis of scoliosis resulted in Lamar's being on and off disability for her last 16 years of work. She went under the knife nine times in three years, 1991 through 1993. She was declared permanently disabled in 2006.

In 2007, Lamar underwent three more surgeries, these at Barnes Hospital in St. Louis. The final one was disaster.

Her phrenic nerve — the main nerve controlling the diaphragm, primary muscle involved in breathing — was nipped during a 14-hour procedure, rendering her dependent on a ventilator. She also developed a blood clot in her leg and suffered a slight stroke. Doctors believed trauma from these events resulted in permanent kidney shutdown.

Transferred to Select Specialty Hospital in Evansville, she was weaned from the ventilator. A complication put her on a breathing machine again. Still on a ventilator some 10 months after the surgery, Lamar said she was being sized up for long-term nursing care with the assumption she'd be on a ventilator for life.

That, she said, is when Grimm, who'd already assisted in one of her surgeries in Louisville, Ky., and attended another in St. Louis as a consultant, stepped out of his specialty and helped get her into Kindred Long Term Care Hospital in Louisville, a facility with good reputation for ventilator-weaning. It took five months, but 13 months after the disastrous surgery — in autumn 2008 — she was home again, ventilator-free.

No remedy was in sight, however, to wean her from her thrice-weekly dialysis treatments.

That would take a kidney transplant.

Long wait

Doreen Lamar has type O blood. It's a good blood type if you're a kidney donor because almost all recipients, regardless of blood type, can receive a kidney from an O donor.

But a type O recipient can receive only a type O kidney. They, of course, are the scarcer because of their versatility.

So Lamar waits.

She waited a year after her 13 months of hospitalization to begin the complicated and time-consuming testing to qualify for a transplant list. She now has been listed for two years, both at Indiana University Hospital in Indianapolis and the University of Cincinnati Hospital.

And she waits.

"I am told, because of a shortage of organs from deceased donors, my wait is three to four years. I'm type O, so that makes it even longer they told me the only hope of getting a kidney sooner is if I can find a living donor," she said.

Statistics were not readily available on how many people die each year awaiting a transplant kidney. But the following was available from the U.S. Department of Health and Human Services: Each day, about 79 people receive transplant organs and 18 people die because the organ they needed was never donated.

Losing a friend

It happens a lot with kidney patients. One of them, late last year, was Carl Elder, in his 70s, a computer whiz like Lamar, a dialysis mate whom she called her "very best friend."

"We played computer games on the iPad when we couldn't get to sleep," Lamar said. "We played word games all night long, and during dialysis, too. It was so refreshing to talk computers with someone that age."

Elder's death hit her hard. She lost a friend — not the only fellow dialysis patient she's watched die — and was reminded Elder's fate could be hers.

"I don't like to think about it, but it's reality," she said. "It's tough when you have a best friend who dies in dialysis. And I can see myself going downhill. Dialysis treatments are hard on you. I can feel myself getting weaker and weaker."

Members of Lamar's immediate family have either diabetic or blood-pressure problems that disqualify them as living donors. So she must hope another donor will come forward on her behalf. Michelle Brockman of Hawesville, Ky., formerly a co-worker at Abbey Press and a booster of living organ donorship, had agreed to donate a kidney for Lamar. But after going through 98 percent of pre-donor testing, she was disqualified. The kidneys of Brockman's husband were failing when he died two years ago of heart disease related to diabetes.

Ironically, a Tell City woman with whom Lamar is not acquainted may have helped Lamar's cause recently when she put living donorship in the public eye. Bobbie Davis, also 56, a security officer, offered just last month to donate a kidney to a Darmstadt couple, each with end-stage kidney disease as a result of Type 1 diabetes and each in need of a transplant. A Mount Vernon, Ind., couple, Lavon and Steve Keitel, also contacted Kerry and Lisa Keck of Darmstadt and offered to donate kidneys after a story about them appeared in the Courier & Press.

Though Lamar is type O and needs a compatible kidney, an incompatible donor could come forward and donate in her name. "The transplant centers have what they call paired donations," Lamar explained. An incompatible donor is placed in an unmatched pool where donorships are swapped with compatible recipients until all unmatched donors and recipients find a match.

"(It) takes longer than finding a type O for me but it is still quicker and better than waiting on a deceased (donor) list," Lamar said. Because there are respiratory caution flags dating back to her 13 months on a ventilator, a living donor's kidney would work better because organs from a living donor usually start working right away. She said fluids would be added to her body to get a deceased donor's kidney functioning, which doctors have told her could cause breathing problems and result in a return to a ventilator.

An 'amazing gal'

Some who know Lamar or have heard the story of what she's been through are amazed her determination. She said: "The main thing that has kept me going is the fact that over the years my spine surgeon has become my best friend and cheerleader, and he has done so much for me and I do not want to let him down."

Those are her words about Dr. John Grimm, who, besides finding a way for Lamar to escape ventilator hell, also arranged pastoral care for her when she was hospitalized and first encouraged her to pursue a transplant.

"When I first got out of the hospital, I didn't want to talk to anyone about transplantation," Lamar recalled. "He kept working on me and working on me until finally I realized, 'Yes, this is really what I want to do.' " Since, she added, "I have been on a mission to get this kidney."

Grimm, who examined Lamar late last month, said he can see her health is waning and hopes her donor comes along soon. "What better gift to give," he said.

Though Grimm agreed he has "tried to facilitate," he insists the victories she's won "she mostly did on her own. She's a pretty amazing gal. She's just very tough and won't give in."

...

 
La Jolla Pharmaceutical Company Announces Development Programs for Lead ... - SYS-CON Media (press release)
image image

SAN DIEGO, CA -- (Marketwire) -- 04/16/12 -- La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) today announced initial product development plans for advancing GCS-100, its first-in-class inhibitor of galectin-3.

On January 20, 2012, we announced the acquisition of GCS-100 from Solana Therapeutics, Inc. This acquisition makes us a leader in the development of therapeutics that target galectin-3, a protein that has been shown to play an important role in chronic organ failure and cancer. The Company believes that GCS-100 is the most advanced galectin-3 inhibitor in development and plans to initially focus its development activities in two areas of great unmet medical need: chronic kidney disease and cancer.

Chronic Kidney Disease: A Significant Unmet Medical Need

The developed world is suffering an epidemic of diabetes and hypertension, both of which cause kidney damage, chronic kidney disease and end-stage renal disease (ESRD). The National Institute of Diabetes and Digestive and Kidney Diseases estimates that 20 million United States adults suffered chronic kidney disease in 2008 [REF 1]. Of these 20 million people, 547,982 received treatment for ESRD and an estimated 88,630 died of ESRD. In total, a staggering $40 billion was spent in the United States on ESRD in 2008. ESRD leads to the need for dialysis and kidney transplantation. In 2008, 16,557 patients in the United States received a kidney transplant. Of these, 10,551 received a kidney from a non-living donor (cadaveric transplant). These transplants are at much higher risk of being rejected due to an attack by the patient's immune system. Despite improvements in therapies designed to suppress rejection by the recipient's immune system, 10% of patients receiving cadaveric transplants suffer acute rejection episodes which increases the risk of ultimate graft failure. In addition, the immunosuppressive therapies given to these patients increase the risk of infection and cancer due to sustained immune suppression.

The Role of Galectin-3 in Chronic Kidney Disease

Chronic organ failure involving the kidney, heart, liver or other organs is caused by fibrosis, or scar formation. Galectin-3 is normally found in most tissues at low concentration, but is up-regulated (increased) in response to injury. Several recent studies conducted by leading investigators have shown that increased circulating levels of galectin-3 are associated with poorer outcomes in patients with heart and kidney failure [REF 2, 3]. Furthermore, a number of preclinical studies have demonstrated a direct, causal role of galectin-3 in tissue fibrosis leading to kidney failure. Specifically, animals that have been genetically engineered to lack galectin-3 do not produce harmful scar formation after kidney injury or transplantation and have better kidney function. [REF 4, 5, 6].

GCS-100 for Chronic Kidney Disease

By inhibiting galectin-3, GCS-100 has the potential to delay or even reverse organ failure by preventing tissue fibrosis. GCS-100 has already been studied in more than 100 patients and has demonstrated an excellent side effect profile with mild-to-moderate, self-limiting rash as the principal side effect observed in clinical trials to date. We plan to initiate a clinical trial this year to study GCS-100 in cancer patients with renal (kidney) insufficiency. We will be evaluating several end points related to renal function, as well as looking at the effect of GCS-100 on plasma levels of galectin-3 and their relation to renal function.

Cancer

The American Cancer Society estimates that over 1.6 million new cases of cancer will be diagnosed in the United States in 2012 [REF 7]. The lifetime chance of developing cancer is 1:2 for men and 1:3 for women. Cancer strikes all ages, races and segments of our society. Despite significant advances in recent years, cancer is the second leading cause of death in the United States, responsible for almost 600,000 deaths annually. Additionally, traditional therapies for cancer do not specifically target the cancer cells and therefore cause significant debilitating side effects. In an effort to specifically target the cancer cells, biologists and drug developers have long sought to harness the patient's own immune system for the treatment of cancer. In recent years, progress has been made on this goal with the successful development and approval of Yervoy? (ipilimumab) for advanced-stage melanoma and Provenge? (sipuleucel-T) for the treatment of advanced-stage prostate cancer. These therapies work by stimulating or assisting the body's active immune response to fight the tumor. Active immune therapies cause the patient's immune system to adapt to the ever-present changes in the tumor. In contrast, passive monoclonal antibody therapies do not stimulate the patient's own immune defenses to combat the cancer and therefore mutating cancer cells can often evade these therapies. Immunotherapy approaches hold particular promise to treat the cancer while sparing normal tissues.

The Role of Galectin-3 in the Body's Immune Response to Cancer

A number of studies have suggested that galectin-3 impairs the active immune system's attack on cancer [REF 8, 9]. Specifically, these publications have shown that cancer cells secrete high levels of galectin-3, which serves to deactivate the body's immune response to the cancer cell.

GCS-100 for Cancer

By antagonizing galectin-3, GCS-100 disrupts this mechanism of immune evasion and has the potential to activate the patient's immune system to fight cancer. Preclinical studies of GCS-100 have shown that GCS-100 can reactivate killer T-cells directed at the cancer that have been silenced by galectin-3 [REF 9]. Because GCS-100's mechanism of immune activation is complementary to those of approved cancer immunotherapies Yervoy and Provenge, there is the potential that GCS-100 will work in synergy with them and similar agents. GCS-100 has been studied in over 100 cancer patient and has demonstrated activity in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and renal cell cancer (RCC). We believe that the safety profile of GCS-100 to date has been excellent, with mild-to-moderate, self-limiting rash as the principal side effect.

We plan on evaluating GCS-100 in combination with Yervoy in preclinical models. This work builds on previous studies in which GCS-100 was shown to be additive or synergistic with several chemotherapeutic and targeted anti-cancer agents. Following successful completion of this study, we plan on initiating a clinical trial in melanoma.

Summary

We are dedicated to developing safe and effective therapies for significant life-threatening diseases including organ failure and cancer. We are attacking these fatal disorders by targeting galectin-3, a member of the galectin family of proteins that is implicated in their pathology. Our lead product candidate against galectin-3, GCS-100, has been tested in more than 100 patients and is generally well tolerated. We have an experienced management team dedicated to accomplishing our corporate milestones, as well as sufficient cash to execute on these near-term activities. Please visit us at http://www.ljpc.com.

REFERENCES

1. Centers for Disease Control and Prevention (CDC). National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services (HHS), CDC, 2010.

2. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 2011; 43: 60-68.

3. Galectin-3 and Outcomes in Patients with End-Stage Renal Disease: Data from the German Diabetes and Dialysis Study, presented by Rudolf de Boer, MD, PhD, Associate Professor of Cardiology at the University of Groningen, the Netherlands; American Heart Association Scientific Presentation, November 2011.

4. Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis. The American Journal of Pathology, 2008; Vol. 172, No. 2: 288-298.

5. Tubular Atrophy and Interstitial Fibrosis After Renal Transplantation Is Dependent on Galectin-3. Transplantation, 2012; Vol. 93, No. 5:477-484.

6. A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transplantation International, 2008; Vol. 21, No. 10: 999-1007.

7. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.

8. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity, 2008; 28:414-424.

9. A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice. Cancer Res 2010; 70:7476-7488.

About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer.

Forward Looking Statement Safe Harbor
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site at http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Company Contact
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
La Jolla Pharmaceutical Company
Phone: (858) 646-6682
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Media Contact:
Michael Rice
LifeSci Advisors, LLC
Phone: (646) 597-6979
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

...

 
<< Start < Prev 451 452 453 454 455 456 457 458 459 460 Next > End >>

Page 451 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.